COMPARISON OF XANTHINE OXIDASE INHIBITORS IN GOUTY PATIENTS WITH HYPERURICEMIA
Abstract
Objective: Febuxostat is more effective/superior to Allopurinol in reducing the serum uric acid (SUA) level in the treatment of hyperuricemic with
gout.
Methods: This randomized control study included 200 hyperuricemic patients with gout, at Multi-center study including Outdoor Departments of
Medicine from four different hospitals of Lahore, Pakistan. Patients age range 18-50 years diagnosis with hyperuricemia and gout, SUA >8 mg/dl
were included while severe renal impairment and alanine aminotransferase and aspartate aminotransferase patients were excluded from the study.
Results: About 200 patients treated with hyperuricemic with gout were randomly divided into four groups (50%) patients were in each group
received different treatment. Out of 200 patients, 118 (59%) were male and 82 (41%) were female with mean age 42.37±9.47 years. Among the
Febuxostat group, patients' success rate of lowering SUA level was found to be 32 (64%) as compared to Allopurinol 16 (32%). Drug compliance was
similar among treatment groups, i.e. Allopurinol and Febuxostat while the trend toward drug compliance in Allopurinol + Vitamin C and Febuxostat +
Vitamin C groups showed similar in number.
Conclusion: Febuxostat is safe and effective to Allopurinol for the treatment of hyperuricemia with gout as the Febuxostat has a significant association
with lowering SUA concentration <6 mg/dl. It is concluded that although Febuxostat is safe and effect alone in gouty patients, but it has somehow a
little effect with Vitamin C especially in patients who are feeble.
Keywords: Febuxostat, Allopurinol, Serum uric acid.
Â
Downloads
References
REFERENCES
Sunkureddi P, Nguyen-Oghalai TU, Karnath BM. Clinical signs of
gout. Hosp Phys 2006;42:39-42.
Cannella AC, Mikuls TR. Understanding treatments for gout. Am J
Manag Care 2005;11 15 Suppl: S451-8.
Chen LX, Schumacher HR. Gout: An evidence-based review. J Clin
Rheumatol 2008;14 5 Suppl: S55-62.
Eggebeen AT. Gout: An update. Am Fam Physician 2007;76:801-8.
Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P,
Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat
in the treatment of the hyperuricemia of gout: The CONFIRMS trial.
Arthritis Res Ther 2010;12(2):R63.
Becker M, et al. Orate-lowering pharmacotherapy with febuxostat or
allopurinol in Black-American subjects with gout. In: Annals of The
Rheumatic Diseases. BMJ Publishing Group British Med Assoc House,
Tavistock Square, London WC1H 9jr, England.
Roch-Ramel F, Guisan B. Renal transport of urate in humans. News
Physiol Sci 1999;14:80-4.
Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y,
Artamonov I, et al. Low uric acid levels in serum of patients with ALS:
Further evidence for oxidative stress? J Neurol Sci 2009;285(1-2):95-9.
Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K,
Economou M, et al. Serum uric acid and multiple sclerosis. Clin Neurol
Neurosurg 2006;108(6):527-31.
Auinger P, Kieburtz K, McDermott MP. The relationship between
uric acid levels and Huntington’s disease progression. Mov Disord
;25(2):224-8.
Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F,
Tsoutsou A, et al. Serum uric acid levels in patients with Parkinson’s
disease: Their relationship to treatment and disease duration. Clin
Neurol Neurosurg 2009;111(9):724-8.
Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, et al. Decreased
plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatr
Psychiatry 2006;21(4):344-8.
Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of
gout in women. JAMA 2010;304(20):2270-8.
Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet
soft drinks, and serum uric acid level: The Third National Health and
Nutrition Examination Survey. Arthritis Rheum 2008;59(1):109-16.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA,
Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and
placebo in reducing serum urate in subjects with hyperuricemia and
gout: A 28-week, phase III, randomized, double-blind, parallel-group
trial. Arthritis Rheum 2008;59(11):1540-8.
Edwards NL. Febuxostat: A new treatment for hyperuricaemia in gout.
Rheumatology (Oxford) 2009;48 Suppl 2:ii15-19.
Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L.
Randomized controlled trial of febuxostat versus allopurinol or placebo
in individuals with higher urinary uric acid excretion and calcium
stones. Clin J Am Soc Nephrol 2013;8(11):1960-7.
Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, et al. Efficacy
and tolerability of febuxostat in hyperuricemic patients with or
without gout: A systematic review and meta-analysis. Clin Ther
;35(2):180-9.
Ernst ME, Fravel MA. Febuxostat: A selective xanthine-oxidase/
xanthine-dehydrogenase inhibitor for the management of hyperuricemia
in adults with gout. Clin Ther 2009;31(11):2503-18.
Teixeira VH, Valente HF, Casal SI, Marques AF, Moreira PA.
Antioxidants do not prevent postexercise peroxidation and may delay
muscle recovery. Med Sci Sports Exerc 2009;41(9):1752-60.
Stamp LK, O’Donnell JL, Frampton C, Drake JM, Zhang M,
Chapman PT. Clinically insignificant effect of supplemental vitamin
C on serum urate in patients with gout: A pilot randomized controlled
trial. Arthritis Rheum 2013;65(6):1636-42.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.